Raphael Pharmaceutical Stock Buy Hold or Sell Recommendation
| RAPH Stock | 0.26 0.00 0.00% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Raphael Pharmaceutical is 'Strong Sell'. The recommendation algorithm takes into account all of Raphael Pharmaceutical's available fundamental, technical, and predictive indicators you will find on this site.
Check out Raphael Pharmaceutical Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Raphael and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Raphael Pharmaceutical. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
Raphael |
Execute Raphael Pharmaceutical Buy or Sell Advice
The Raphael recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Raphael Pharmaceutical. Macroaxis does not own or have any residual interests in Raphael Pharmaceutical or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Raphael Pharmaceutical's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Raphael Pharmaceutical Trading Alerts and Improvement Suggestions
| Raphael Pharmaceutical generated a negative expected return over the last 90 days | |
| Raphael Pharmaceutical has high historical volatility and very poor performance | |
| Raphael Pharmaceutical has some characteristics of a very speculative penny stock | |
| Raphael Pharmaceutical has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (1.62 B) with profit before overhead, payroll, taxes, and interest of 0. | |
| Raphael Pharmaceutical generates negative cash flow from operations |
Raphael Pharmaceutical Returns Distribution Density
The distribution of Raphael Pharmaceutical's historical returns is an attempt to chart the uncertainty of Raphael Pharmaceutical's future price movements. The chart of the probability distribution of Raphael Pharmaceutical daily returns describes the distribution of returns around its average expected value. We use Raphael Pharmaceutical price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Raphael Pharmaceutical returns is essential to provide solid investment advice for Raphael Pharmaceutical.
| Mean Return | -1.28 | Value At Risk | 0.00 | Potential Upside | 0.00 | Standard Deviation | 10.37 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Raphael Pharmaceutical historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Raphael Pharmaceutical Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Raphael Pharmaceutical or Raphael sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Raphael Pharmaceutical's price will be affected by overall otc stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Raphael otc's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -1.58 | |
β | Beta against Dow Jones | 2.39 | |
σ | Overall volatility | 10.53 | |
Ir | Information ratio | -0.14 |
Raphael Pharmaceutical Volatility Alert
Raphael Pharmaceutical is displaying above-average volatility over the selected time horizon. Raphael Pharmaceutical is a potential penny stock. Although Raphael Pharmaceutical may be in fact a good instrument to invest, many penny otc stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Raphael Pharmaceutical. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Raphael instrument if you perfectly time your entry and exit. However, remember that penny otcs that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Raphael Pharmaceutical Fundamentals Vs Peers
Comparing Raphael Pharmaceutical's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Raphael Pharmaceutical's direct or indirect competition across all of the common fundamentals between Raphael Pharmaceutical and the related equities. This way, we can detect undervalued stocks with similar characteristics as Raphael Pharmaceutical or determine the otc stocks which would be an excellent addition to an existing portfolio. Peer analysis of Raphael Pharmaceutical's fundamental indicators could also be used in its relative valuation, which is a method of valuing Raphael Pharmaceutical by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Raphael Pharmaceutical to competition |
| Fundamentals | Raphael Pharmaceutical | Peer Average |
| Return On Asset | -19.04 | -0.14 |
| Shares Outstanding | 15.62 M | 571.82 M |
| EBITDA | (1.63 B) | 3.9 B |
| Net Income | (1.62 B) | 570.98 M |
| Book Value Per Share | (0) X | 1.93 K |
| Cash Flow From Operations | (1.42 M) | 971.22 M |
| Market Capitalization | 17.19 M | 19.03 B |
| Total Asset | 422 K | 29.47 B |
| Net Asset | 422 K |
Raphael Pharmaceutical Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Raphael . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Raphael Pharmaceutical Buy or Sell Advice
When is the right time to buy or sell Raphael Pharmaceutical? Buying financial instruments such as Raphael OTC Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Raphael Pharmaceutical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Recreation Thematic Idea Now
Recreation
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Recreation theme has 33 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Recreation Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Raphael OTC Stock
Raphael Pharmaceutical financial ratios help investors to determine whether Raphael OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Raphael with respect to the benefits of owning Raphael Pharmaceutical security.